bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer in Cambridge, Massachusetts and Seattle, Washington.
BLUE’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent ß-thalassemia, and severe sickle cell disease. The company's lead product candidate in oncology is bb2121, a chimeric antigen receptor T cell product candidate that is in a Phase I trial for the treatment of relapsed/refractory multiple myeloma.
BLUE has a strategic collaborations with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Kite Pharma (now Gilead). to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus. It also has strategic collaborations with Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications; and TC BioPharm to research and develop gamma delta CAR T cell product candidates for cancer immunotherapy.
BLUE was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
April 8, 2024
RegMed Investors (RMi) Closing Bell: what’s moving the sector?
April 5, 2024
RegMed Investors (RMi) Closing Bell: economic circumstances drove a 5 session/weekly downside
April 4, 2024
RegMed Investors (RMi) Closing Bell: economics undermine sector’s share pricing before jobs report
April 4, 2024
RegMed Investors’ (RMi) pre-open: missing the beat or beating the miss?
April 3, 2024
RegMed Investors (RMi) Closing Bell: The switch is still flipped
April 2, 2024
RegMed Investors (RMi) Closing Bell: weakness is more of a wipe-out
April 2, 2024
RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results
April 2, 2024
RegMed Investors’ (RMi) pre-open: after a dip and Monday’s trip, caution
April 1, 2024
RegMed Investors (RMi) Closing Bell: An early share pricing eclipse in first session of April?
35 companies, 1 interpreter!
Insight, foresight and recommendation
bluebird Bio (BLUE) – BLUE has been on a tear since 8/21/17 with some dips as January opened at $181.90 with a 1/9 low of $169.50; jumping 2/1 to $205.25 slipping to $191.50 on 2/09 with a pricing of $213.25 on 2/16 ... WHO can argue with this momentum. Celgene's (CELG) option and ownership is a solid foundation ... yet, why any buy-out at this price? It will dip, slip and return but, ebb over time ... yet worth "playing" the pains and gains
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors